Skip to main content
. 2019 Jul 11;9(3):e226–e234. doi: 10.1055/s-0039-1693163

Table 3. Demographics for study participants who did and did not develop BV during pregnancy a .

BV developed during pregnancy ( n  = 16) a No BV developed during pregnancy ( n  = 216) p -Value
Age (y) b 26.5 (±5.1) 29 (±4.7) 0.022
BMI b 26.1 (±7.5) 26.0 (±5.7) 0.13
Gravidity c 3 (2–4) 2 (1–3) 0.43
Parity c 1 (1–2) 1 (0–2) 0.19
Race/ethnicity
 Caucasian 4 (25%) 90 (41.7%) 0.42
 African American 6 (37.5%) 62 (28.7%)
 Hispanic 6 (37.5%) 64 (29.6%)
Insurance type
 Self-pay/none 4 (25%) 51 (23.6%) 0.32
 Public insurance 7 (43.8%) 60 (27.8%)
 Private insurance 5 (31.3%) 105 (48.6%)
Highest education level
 More than high school 8/16 (50%) 142/216 (65.7%) 0.21
 Less than high school 8/16 (50%) 74/216 (34.2%)
Sexually transmitted infections in pregnancy
 Gonorrhea 1/16 (6.3%) 1/216 (0.46%) 0.14
 Chlamydia 2/16 (12.5%) 9/216 (4.2%) 0.17
 Trichomonas 1/16 (6.3%) 8/216 (3.7%) 0.48
 Syphilis 0 0 0
 Herpes simplex virus 1/16 (6.3%) 9/215 (4.19%) 0.52
 HIV (prevalent) 0 0 0
Mean 25(OH)D concentration in pregnancy (ng/mL)
 8–15 wk (visit 1) 22.05 (±8.4) 26.3 (±9.6) 0.72
 21–28 wk (visit 4) 36.5 (±12.8) 38.7 (±15.1) 0.61
 31–41 wk (visit 7) 47.6 (±15.9) 42.2 (±19.0) 0.98
Pregnancy outcome of interest
 Gestational HTN 0 8/216 (3.7%) 1.0
 Preeclampsia 0 9/216 (4.2%) 1.0
 Chorioamnionitis 1/16 (6.3%) 6/216 (2.8%) 0.4
 Preterm birth 1/16 (6.3%) 9/216 (4.2%) 0.52
Vitamin D treatment group allocation
 Treatment group (vitamin D supplement = 4,000 IU) 10/16 (62.5%) 114/216 (52.8%) 0.45

Abbreviations: BV, bacterial vaginosis; HIV, human immunodeficiency virus; HTN, hypertension; 25(OH)D, 25-hydroxyvitamin D.

a

Women with BV at baseline were excluded from this analysis.

b

Continuous variables are reported as mean values with standard deviation. Univariate analysis performed by Wilcoxon's rank-sum test.

c

Median with interquartile range. Categorical variables were analyzed by chi-square test and Fisher's exact test.